Phase III study of ACP-196 vs Ibrutinib in High Risk CLL

Clinical Trial Grant

Duke Scholars

Principal Investigator Danielle Marie Brander Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Acerta Pharma

Start Date

June 1, 2016

End Date

May 31, 2022

Administered By

Duke Cancer Institute

Awarded By

Acerta Pharma

Start Date

June 1, 2016

End Date

May 31, 2022